Browsing by Author "Arpí Llucià, Oriol"

Sort by: Order: Results:

  • A comparison of RNA-Seq results from paired formalin-fixed paraffin-embedded and fresh-frozen glioblastoma tissue samples
    Esteve-Codina, Anna; Arpí Llucià, Oriol; Martínez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira Guerín, Ana; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda Quitllet, Francisco; de la Iglesia, Nuria; Balaña, Carmen; GLIOCAT Group (Public Library of Science (PLoS), 2017)
    The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation sequencing ...
  • CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer
    Luque, Melani; Cristóbal, Ion; Sanz Álvarez, Marta; Santos, Andrea; Zazo, Sandra; Eroles, Pilar; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; García-Foncillas, Jesús; Rojo, Federico (MDPI, 2022)
    Together with its reported ability to modulate AKT phosphorylation (p-AKT) status in several tumor types, the oncoprotein CIP2A has been described to induce breast cancer progression and drug resistance. However, the ...
  • Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
    Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
    Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
    Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico (e-Century Publishing, 2017)
    Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to ...
  • Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy
    Carrato, Cristina; Alameda Quitllet, Francisco; Esteve-Codina, Anna; Arpí Llucià, Oriol; Gut, Marta; Menéndez, Silvia; Balana, Carmen (American Association for Cancer Research (AACR), 2020)
    Purpose: Molecular subtype classifications in glioblastoma may detect therapy sensitivities. Immunohistochemistry would potentially allow the identification of molecular subtypes in routine clinical practice. Experimental ...
  • HER-family ligands promote acquired resistance to trastuzumab in gastric cancer
    Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...
  • In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
    Hernandez, Ainhoa; Muñoz-Mármol, Ana M.; Esteve-Codina, Anna; Alameda Quitllet, Francisco; Carrato, Cristina; Pineda, Estela; Arpí Llucià, Oriol; Martinez-García, Maria; Mallo, Mar; Gut, Marta; Barco Berrón, Sonia del; Gallego, Oscar; Dabad, Marc; Mesia, Carlos; Bellosillo Paricio, Beatriz; Domenech, Marta; Vidal, Noemí; Aldecoa, Iban; Iglesia, Nuria de la; Balana, Carmen (Nature Research, 2022)
    RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in ...
  • mTOR inhibition and T-DM1 in HER2-positive breast cancer
    Casadevall Aguilar, David; Hernández Prat, Anna, 1984-; García-Alonso, Sara; Arpí Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia Valenzuela, Cristina, 1990-; Morancho Armisen, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi Mehrjardi, Mohammad Ali; Eroles, Pilar; Cejalvo, Juan M.; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2022)
    In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR ...
  • Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models
    Hernández Prat, Anna, 1984-; Rodriguez-Vida, Alejo; Juanpere, Nuria; Arpí Llucià, Oriol; Menéndez, Silvia; Soria-Jiménez, Luis; Martínez, Alejandro; Iarchouk, Natalia; Rojo, Federico; Albanell Mestres, Joan; Brake, Rachael; Rovira Guerín, Ana; Bellmunt Molins, Joaquim, 1959- (American Association for Cancer Research (AACR), 2019)
    Advanced bladder cancer is associated with a poor prognosis and limited treatment options. The PI3K/AKT/mTOR pathway is frequently activated in this disease and can be a potential therapeutic target for treatment intervention. ...
  • PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
    Rincón, Raúl; Cristóbal, Ion; Zazo, Sandra; Arpí Llucià, Oriol; Menendez Romero, Silvia; Manso, Rebeca; Lluch, Ana; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; García-Foncillas, Jesús; Madoz-Gúrpide, Juan; Rojo, Federico (Impact Journals, 2015)
    The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A ...
  • RNA-Sequencing and immunohistochemistry reveal ZFN7 as a stronger marker of survival than molecular subtypes in G-CIMP-negative glioblastoma
    Esteve-Codina, Anna; Alameda Quitllet, Francisco; Arpí Llucià, Oriol; Gut, Marta; Dabad, Marc; Balana, Carmen (American Association for Cancer Research (AACR), 2021)
    Purpose: Glioblastoma is the most aggressive brain tumor in adults and has few therapeutic options. The study of molecular subtype classifications may lead to improved prognostic classification and identification of new ...
  • Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
    Hardy-Werbin, Max; Rocha, Pedro P.; Arpí Llucià, Oriol; Taus García, Álvaro; Nonell Mazelón, Lara; Duran Jordà, Xavier, 1974-; Villanueva, Xavier; Joseph-Pietras, Deborah; Nolan, Luke; Danson, Sarah; Griffiths, Richard; López-Botet, Miguel; Rovira Guerín, Ana; Albanell Mestres, Joan; Ottensmeier, Christian; Arriola Aperribay, Edurne (Taylor & Francis, 2019)
    Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory ...
  • The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...
  • The hippo pathway transducers YAP1/TEAD induce acquired resistance to trastuzumab in HER2-Positive breast cancer
    González-Alonso, Paula; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (MDPI, 2020)
    Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the ...